

Ref: FOI/CAD/ID 3936

Please reply to:  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent, ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

7 April 2017

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to PDL1 testing.

1. *Do you currently offer a clinical testing service for PD-L1 in non-small cell lung carcinoma (NSCLC) as off the beginning of 2017?*
2. *How is PD-L1 testing in NSCLC normally requested by the clinician? (please select all that apply)*
3. *If requested as part of a NSCLC panel of tests, how is PD-L1 testing performed in the lab*
4. *What sample types are processed by the lab for NSCLC testing (EGFR/ALK/PD-L1)? (please select all that apply)*
5. *What is the number of NSCLC samples being tested (or sent-out) are tested for?:*
6. *What proportion of PD-L1 NSCLC samples tested are cytology/ cytological cell block samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)*
7. *What proportion of PD-L1 NSCLC samples are NOT tested because the samples are EBUS/cytology samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)*
8. *What methods are used for PD-L1 testing in NSCLC and their associated clinical cut-off? (please select all that apply)*
9. *What is the clinical cut offs are used in relation to the antibodies selected above?*
10. *What IHC staining platform(s) are used in the laboratory that performs the PD-L1 testing e.g. Ventana, Dako, Leica, Menarini, Shandon, Labvision, etc? (If possible, please supply the model of the platform)*
11. *What percentage of samples tested have ≥1% PD-L1 expression?*
12. *What percentage of samples tested have ≥50% PD-L1 expression?*
13. *What is the average turnaround time from sample receipt to report being issued?*
14. *Are there bottlenecks that prevent this turnaround time from being quicker?*
15. *Who pays for DLBCL testing?*

1. Yes but send out to an external laboratory.  
 QEH Birmingham
2. As part of a NSCLC panel of tests (PD-L1, EGFR, ALK) for new diagnosed NSCLC samples
3. In parallel with EGFR and ALK
4. Needle Core Biopsy  
EBUS cytological cell block
5.  
ALK Please specify number: 15 approx. (per month)  
EGFR Please specify number: 15 approx. (per month)  
PD-L1 Please specify number: 15 approx. (per month)
6. Unknown
7. Unknown
8. Dako PD-L1 IHC 22C3 pharmDx
9. Report states % stained. Clinicians follow NICE guidelines.
10. Unknown model but DAKO system.
11. Unknown (not monitored). This would be a manual audit exercise.
12. Unknown (not monitored)
13. 7-10 days
14. None identified
15. Pharma initiative, please specify details: DLBCL is not to do with lung cancer / PDL1 testing (Diffuse Large B Cell Lymphoma). If the question should read who pays for PDL1 testing? Then the response is a pharma initiative.